AliveDx
Generated by Meeveem AI
"Advanced in-vitro diagnostics that shorten time-to-diagnosis for autoimmune and allergy testing"
Eysins
•251 - 500 Employees
•Biotechnology
About AliveDx
AliveDx develops in-vitro diagnostic solutions that enable faster disease detection and diagnosis across autoimmune, allergy, and transfusion testing. The company's MosaiQ automated microarray platform and LumiQ immunofluorescence system deliver workflow efficiency to laboratories while reducing the time clinicians need to make critical care decisions. Healthcare professionals, laboratory teams, and patients benefit from solutions designed to improve clinical decision-making and laboratory productivity. By combining 30 years of diagnostic expertise with innovative platforms, AliveDx addresses complex diagnostic challenges for conditions including vasculitis, connective tissue diseases, and celiac disease.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
400
Team Members
2007
Founded
Private Equity
Funding
Hybrid
Work Environment
Our Vision
A healthcare system where diagnostic insights arrive fast enough to transform every patient's care journey and clinical outcomes.
Our Mission
At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life.